Chief Scientific Officer

Hilde brings over 20 years of research and development experience in drug discovery & development, including antibody fragment (protein) discovery and early development, as well as technology development, and is inventor of more than 20 patent applications.

Prior to joining Biotalys in 2018, Hilde served as Innovation Manager of the Vaccine & Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp, Belgium, aimed at integrating vaccine and microbiological research.

Before that, Hilde worked at Ablynx (now part of Sanofi) where she held several senior positions, translating drug development projects from discovery up to Phase II clinical trials. She also played a key role in landmark deals for the Company. She started her career at the Flemish Institute for Biotechnology (VIB) as Principal Investigator of the Department of Molecular and Cellular Immunology with focus on immunology and translational research in vaccine development and antibody-based technologies, including biomedical applications of single domain antibody fragments.

Hilde obtained her PhD in Biological Sciences at the University of Brussels (VUB), Belgium.